<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>350</serviceExecutionTime><Drug id="18046"><DrugName>99mTc-glucarate</DrugName><DrugNamesKey><Name id="42787488">AMISCAN</Name></DrugNamesKey><DrugSynonyms><Name><Value>99mTc-glucarate</Value></Name><Name><Value>AMISCAN</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>technetium-99m glucarate</Value></Name><Name><Value>acute mycardial infarction imaging, Draximage/MTTI</Value></Name><Name><Value>acute mycardial infarction imaging, Draximage/Molecular Targeting Technology</Value></Name><Name><Value>99mTc-D-glucaric acid</Value></Name><Name><Value>technetium-99m-D-glucaric acid</Value></Name><Name><Value>99mTc-GLA</Value></Name><Name><Value>technetium-99m-GLA</Value></Name><Name><Value>BTSCAN</Value></Name></DrugSynonyms><CompanyOriginator id="25620">Molecular Targeting Technologies Inc</CompanyOriginator><CompaniesPrimary><Company id="25620">Molecular Targeting Technologies Inc</Company></CompaniesPrimary><CompaniesSecondary><Company id="25117">DRAXIMAGE</Company></CompaniesSecondary><CrossReferences><SourceEntity id="18046" type="Drug"><TargetEntity id="283791" type="siDrug">Technetium-99m glucarate</TargetEntity></SourceEntity><SourceEntity id="25117" type="Company"><TargetEntity id="5035524227" type="organizationId">Draximage Inc</TargetEntity></SourceEntity><SourceEntity id="25620" type="Company"><TargetEntity id="4296748458" type="organizationId">Molecular Targeting Technologies Inc</TargetEntity></SourceEntity><SourceEntity id="224" type="ciIndication"><TargetEntity id="10028596" type="MEDDRA"></TargetEntity><TargetEntity id="D009203" type="MeSH"></TargetEntity><TargetEntity id="-998451372" type="omicsDisease"></TargetEntity><TargetEntity id="226" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="49" type="ciIndication"><TargetEntity id="C50" type="ICD10"></TargetEntity><TargetEntity id="10006279" type="MEDDRA"></TargetEntity><TargetEntity id="D001943" type="MeSH"></TargetEntity><TargetEntity id="-436099203" type="omicsDisease"></TargetEntity><TargetEntity id="588" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C2">Phase 2 Clinical</PhaseHighest><IndicationsPrimary><Indication id="224">Myocardial infarction</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="49">Breast tumor</Indication><Indication id="651">Cancer</Indication></IndicationsSecondary><ActionsSecondary><Action id="1617">Radiopharmaceutical</Action><Action id="4155">Imaging agent</Action><Action id="7210">Cardiovascular diagnostic agent</Action><Action id="7212">Endocrine diagnostic agent</Action><Action id="7220">Neoplasm diagnostic agent</Action></ActionsSecondary><Technologies><Technology id="724">Radiolabeling</Technology><Technology id="603">Systemic formulation unspecified</Technology><Technology id="731">Imaging</Technology><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="750">Freeze drying</Technology></Technologies><LastModificationDate>2018-01-22T16:34:22.000Z</LastModificationDate><ChangeDateLast>2017-04-06T00:00:00.000Z</ChangeDateLast><AddedDate>1998-06-16T13:39:09.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="25117" linkType="Company"&gt;&lt;/ulink&gt;&lt;ulink linkID="25620" linkType="Company"&gt;Molecular Targeting Technologies&lt;/ulink&gt; (MTTI) is developing injectable 99mTc-glucarate  as a potential lyophilized imaging agent for the diagnosis of acute myocardial infarction (AMI) as AMISCAN  [&lt;ulink linkID="289510" linkType="Reference"&gt;289510&lt;/ulink&gt;], [&lt;ulink linkID="1002753" linkType="Reference"&gt;1002753&lt;/ulink&gt;], [&lt;ulink linkID="1395784" linkType="Reference"&gt;1395784&lt;/ulink&gt;]. By early 2003, phase II trials for AMI were ongoing [&lt;ulink linkID="485697" linkType="Reference"&gt;485697&lt;/ulink&gt;], [&lt;ulink linkID="487268" linkType="Reference"&gt;487268&lt;/ulink&gt;]. In June 2012, the program was listed as being in phase II development for AMI detection [&lt;ulink linkID="1298442" linkType="Reference"&gt;1298442&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The company was previously developing 99mTc-glucarate  as a potential imaging agent for the diagnosis of breast cancer as BTSCAN [&lt;ulink linkID="289510" linkType="Reference"&gt;289510&lt;/ulink&gt;], [&lt;ulink linkID="1002753" linkType="Reference"&gt;1002753&lt;/ulink&gt;]. By April 2009, a phase II study in breast cancer had been completed [&lt;ulink linkID="1002753" linkType="Reference"&gt;1002753&lt;/ulink&gt;]. In June 2012, the program was listed as being in phase II development for breast cancer detection [&lt;ulink linkID="1298442" linkType="Reference"&gt;1298442&lt;/ulink&gt;]. However, by March 2013, BTSCAN was no longer listed on the company's development pipeline [&lt;ulink linkID="1395784" linkType="Reference"&gt;1395784&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By June 2005, the agent was in clinical trials in Italy for tumor detection [&lt;ulink linkID="609837" linkType="Reference"&gt;609837&lt;/ulink&gt;]; however, no further development was reported in Italy for this indication.&lt;/para&gt;&lt;para&gt;MTTI was previously collaborating with &lt;ulink linkID="25117" linkType="Company"&gt;DRAXIMAGE&lt;/ulink&gt; in the development of 99mTc-glucarate. However, in August 2004, &lt;ulink linkID="15659" linkType="Company"&gt;DRAXIS Health Inc&lt;/ulink&gt;, the parent company of DRAXIMAGE, announced that it was ceasing further development of the agent. This was due to the results of an interim analysis of the images from the phase II trial, which showed that although 99mTc-glucarate was very clear in definitive myocardial infarction, it was insufficiently precise in very early equivocal infarction [&lt;ulink linkID="554323" linkType="Reference"&gt;554323&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In May 2000, DRAXIMAGE filed an IND for 99mTc-glucarate with both the FDA and the Canadian Therapeutic Products program. By that time, 99mTc-glucarate had proved its efficacy in several clinical trials, including a recent study of 28 patients, that demonstrated 99mTc-glucarate could be used to identify and localize AMI both early and accurately [&lt;ulink linkID="365198" linkType="reference"&gt;365198&lt;/ulink&gt;]. In July 2000, DRAXIMAGE received permission from the FDA and Health Canada's Therapeutic Products program to initiate a phase I study for 99mTc-glucarate [&lt;ulink linkID="374111" linkType="reference"&gt;374111&lt;/ulink&gt;]. In February 2001, DRAXIMAGE received permission from the FDA and Canadian Therapeutic Products program and began further phase II trials of 99mTc-glucarate [&lt;ulink linkID="398902" linkType="reference"&gt;398902&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Myocardial infarction&lt;/subtitle&gt;By  January 2008, data from an open-label, non-randomized, single arm phase II trial conducted in 100 chest pain patients had demonstrated positive 99mTc-glucarate myocardial uptake.  At that time, analyzation of data was ongoing [&lt;ulink linkID="1396908" linkType="Reference"&gt;1396908&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2006, clinical data on 99mTc-glucarate were presented at the 53rd SNM meeting in San Diego, CA. Patients (n = 11) with suspected acute myocardial infarction and chest pain for up to 12 h were administered approximately 900 MBq of 99mTc-glucarate. SPECT imaging was conducted 1 to 3 h later. Four patients underwent percutaneous transluminal coronary angioplasty (PTCA) and the remaining seven patients did not receive perfusion therapy. All patients that had undergone PCTA had positive 99mTc-glucarate uptake within 1.5 h of 99mTc-glucarate administration. Six out of the seven patients that had not received perfusion therapy had distinct 99mTc-glucarate uptake within acute myocardial infarction regions. Uptake levels ranged from very high to only just above the blood pool activity [&lt;ulink linkID="671739" linkType="Reference"&gt;671739&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By early 2003, AMISCAN (structure shown) had been successfully tested in AMI in trials in Italy and Spain; North American phase I trials had  been completed and phase II trials were ongoing [&lt;ulink linkID="485697" linkType="Reference"&gt;485697&lt;/ulink&gt;], [&lt;ulink linkID="487268" linkType="Reference"&gt;487268&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By November 1999, the results of the first 99mTc-glucarate clinical trials showed that it could satisfactorily identify and localize AMI earlier than conventional techniques [&lt;ulink linkID="346065" linkType="reference"&gt;346065&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Cancer&lt;/subtitle&gt;By April 2009, a phase II study had been completed in 31 patients with suspected or confirmed breast cancer. There were no false positives and imaging with 99mTc-glucarate identified 19 of 20 confirmed cancer cases [&lt;ulink linkID="1002753" linkType="Reference"&gt;1002753&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2005, clinical data on 99mTc-glucarate were presented at the 52nd SNM meeting in Toronto, Canada. The agent was compared to &lt;ulink linkID="6318" linkType="Drug"&gt;99mTc-sestamibi&lt;/ulink&gt; for the detection of bone marrow involvement in 10 multiple myeloma patients. Confirmation and staging was performed by MRI and bone marrow biopsy, and was followed within 10 day by whole body scintigraphy 20 min after 99mTc-sestamibi injection and 1 h after 99mTc-glucarate 740 MBq injection. 99mTc-glucarate visualized focal accumulation even in the presence of diffuse 99mTc-sestamibi uptake, and performed better than 99mTc-sestamibi in the presence of focal lesions only, especially those in the spine [&lt;ulink linkID="609837" linkType="Reference"&gt;609837&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In June 2008, at the 55th Society of Nuclear Medicine (SNM) Annual meeting in New Orleans, LA,  data were presented from a study in dogs showing the feasibility of  simultaneous dual imaging of myocardial infarction using 99mTc-glucarate and 201TI SPECT/PT [&lt;ulink linkID="916934" linkType="Reference"&gt;916934&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2005, preclinical data on 99mTc-glucarate were presented at the 52nd SNM meeting in Toronto, Canada. SCID mice bearing A549 lung cancer xenografts received 185 MBq of the agent via jugular vein catheter (n =7) or tail vein injection (n = 7). The first groups were imaged using FASTSPECT every min for 30 min, and were then imaged for 5 min, every 15 min, for 2 h. The second group were imaged for 5 to 15 min at 10 min and 2, 4, 6 and 24 h. Tumors were visible by 10 min, but the tumor/non tumor ratio peaked later: at 6 h it was 6.78, as compared with 3.61 at 2 h and 4.65 at 24 h [&lt;ulink linkID="609261" linkType="Reference"&gt;609261&lt;/ulink&gt;], [&lt;ulink linkID="609337" linkType="Reference"&gt;&lt;/ulink&gt;&lt;ulink&gt;&lt;/ulink&gt;&lt;ulink&gt;&lt;/ulink&gt;&lt;ulink linkID="609337" linkType="Reference"&gt;609337&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By June 1998, DRAXIMAGE's preclinical studies indicated that 99mTc-glucarate had the potential to allow detection and localization of acute myocardial infarction within a few hours of onset, with little delay between injection and imaging [&lt;ulink linkID="289510" linkType="reference"&gt;289510&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="25620">Molecular Targeting Technologies Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="224">Myocardial infarction</Indication><StatusDate>1998-11-23T00:00:00.000Z</StatusDate><Source id="305904" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25117">DRAXIMAGE</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="224">Myocardial infarction</Indication><StatusDate>2004-08-12T00:00:00.000Z</StatusDate><Source id="554323" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25117">DRAXIMAGE</Company><Country id="IT">Italy</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="224">Myocardial infarction</Indication><StatusDate>2004-08-12T00:00:00.000Z</StatusDate><Source id="554323" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25117">DRAXIMAGE</Company><Country id="ES">Spain</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="224">Myocardial infarction</Indication><StatusDate>2004-08-12T00:00:00.000Z</StatusDate><Source id="554323" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25117">DRAXIMAGE</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="224">Myocardial infarction</Indication><StatusDate>1998-11-23T00:00:00.000Z</StatusDate><Source id="554323" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25620">Molecular Targeting Technologies Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2013-03-26T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25620">Molecular Targeting Technologies Inc</Company><Country id="IT">Italy</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2007-01-21T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="25620">Molecular Targeting Technologies Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2005-06-22T00:00:00.000Z</StatusDate><Source id="609337" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25620">Molecular Targeting Technologies Inc</Company><Country id="IT">Italy</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2005-07-21T00:00:00.000Z</StatusDate><Source id="609837" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25620">Molecular Targeting Technologies Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2009-04-23T00:00:00.000Z</StatusDate><Source id="1002753" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25117">DRAXIMAGE</Company><Country id="ES">Spain</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="224">Myocardial infarction</Indication><StatusDate>2003-04-01T00:00:00.000Z</StatusDate><Source id="485697" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25117">DRAXIMAGE</Company><Country id="IT">Italy</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="224">Myocardial infarction</Indication><StatusDate>2003-04-01T00:00:00.000Z</StatusDate><Source id="485697" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25117">DRAXIMAGE</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="224">Myocardial infarction</Indication><StatusDate>2000-05-05T00:00:00.000Z</StatusDate><Source id="365198" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25117">DRAXIMAGE</Company><Country id="CA">Canada</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="224">Myocardial infarction</Indication><StatusDate>1998-06-16T13:39:09.000Z</StatusDate><Source id="289510" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25117">DRAXIMAGE</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="224">Myocardial infarction</Indication><StatusDate>2001-02-14T00:00:00.000Z</StatusDate><Source id="398902" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1003756">Jubilant Life Sciences Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="25620">Molecular Targeting Technologies Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>[C@H]([C@@H]([C@@H](C(=O)O)O)O)([C@H](C(=O)O)O)O.[C@H]([C@@H]([C@@H](C(=O)O)O)O)([C@H](C(=O)O)O)O.O=[99Tc]</Smiles></StructureSmiles><Deals><Deal id="122075" title="DRAXIMAGE to collaborate with MTTI on imaging agents worldwide"/><Deal id="145316" title="NHLBI to award Molecular Targeting Technologies funding to develop 99mTc-glucarate for cardiac ischemia"/></Deals><PatentFamilies><PatentFamily id="1694381" number="WO-2005042766" title="Technetium-99m glucarate methods of use for monitoring tissues"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Molecular Targeting Technologies Inc" id="25620"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>